Microsoft word - lonza acquires the bioproducts manufacturing division of ucb
Lonza Acquires the Bioproducts Manufacturing Division
Basel (Switzerland) and Brussels (Belgium), January 17, 2006 - Lonza and UCB jointly announce that
Lonza, a global peptide custom manufacturer, has acquired the Bioproducts manufacturing division of
UCB ("Bioproducts") for an amount of EUR 120 million.
UCB-Bioproducts has been active in chemical peptide manufacturing for over 20 years, and has
developed considerable capabilities and expertise during this period. This division, with approximately
300 employees, is located in Braine-l'Alleud just outside of Brussels, Belgium.
Stefan Borgas, Chief Executive Officer of Lonza commented: "We are quite excited to welcome the fully
dedicated, highly qualified and entrepreneurial UCB colleagues to join our global business. With this
acquisition Lonza further strengthens its position as a worldwide leader in custom peptide manufacturing
by continuing to develop the Braine l'Alleud site as a global centre of excellence for the development and
manufacture of peptides." Lonza has participated in peptide production since 1997. Both companies are
very well acknowledged in the worldwide market and have expertise in peptide manufacturing .
Roch Doliveux, Chief Executive Officer of UCB said: "This transaction is another strategic move towards
UCB's quest of becoming a global biopharmaceutical leader focusing on research, development, and
commercialisation of therapeutic solutions for severe diseases. The reputation and strategic focus of
Lonza as a leading contract manufacturer will enable the Bioproducts division to further strengthen its
leading position and join a group focused on custom manufacturing with whom UCB has several other
long term manufacturing relationships. We would like to pay tribute to everyone involved in making the
Bioproducts business such a success, for their skill and dedication."
The expertise in liquid phase technology developed by Bioproducts complements Lonza's existing skills in
peptide production, with a focus on large-scale solid phase peptide synthesis, and recombinant
fermentation production. There are three current technologies available to produce peptides: liquid phase
peptide synthesis, solid phase peptide synthesis and recombinant technology. The first two are chemical
syntheses and the third is microbial fermentation. By merging the businesses, Lonza will be the only
contract manufacturer with a historically successful track record of providing Active Pharmaceutical
Ingredients (API) from any of the three peptide technologies.
Lonza is now capable of providing the market with additional capacity quickly. This acquisition provides
Lonza with another global site to serve its customer base, in addition to the three sites, in Switzerland,
the United States and Czech Republic, thus significantly reducing customers' sourcing risks.
Lonza, a chemical and biotechnology company, driven by the life sciences, generated sales of CHF 2.18
billion in 2004. Headquartered in Switzerland, Lonza operates 18 production and R&D sites around the
world. Its 5,700 employees are passionately committed to delivering sustainable value to their
customers. Lonza is the leading custom manufacturers of chemical intermediates, active ingredients and
biopharmaceuticals for the pharmaceutical and agrochemical industries. On the basis of organic chemical,
oleochemical and biotechnology platforms, Lonza creates value-added solutions for the nutrition, hygiene
& personal care, wood & water treatment and industrial specialty markets. Lonza also offers polymer
intermediates, resins and compounds. Further information can be found on our website www.lonza.com.
UCB (www.ucb-group.com) is a global biopharmaceutical leader with headquarters in Brussels, Belgium,
specialising in the fields of central nervous system disorders, inflammatory diseases, and oncology. UCB
key products are Keppra®
function regulator), Tussionex®
(antitussive) and Metadate(TM) / Equasym XL(TM) (attention
deficit/hyperactivity disorder). UCB employs over 8,500 people operating in over 40 countries. UCB is
listed on Euronext Brussels (UCB / UCBBt.BR / UCB BB).
FUNDAÇÃO INSTITUTO CAPIXABA DE PESQUISAS EM CONTABILIDADE, ECONOMIA E FINANÇAS JULIANA TALHATE PERFIL DE CONSUMO DE MEDICAMENTOS DE PACIENTES COM DIABETES MELLITUS TIPO II VITÓRIA JULIANA TALHATE PERFIL DE CONSUMO DE MEDICAMENTOS DE PACIENTES COM DIABETES MELLITUS TIPO II Dissertação apresentada ao Programa de Pós-Graduação pesquisa Marketi
medien recht Register 2003 Zeitschrift für Medien- und KommunikationsrechtRedaktion und Verlag: 1040 Wien, Danhausergasse 6, Tel. 01/505 27 66, Fax 505 27 66-15E-Mail: firstname.lastname@example.org http://www.medien-recht.com Beiträge Abgabenrecht – „MA 2412“ und der Schutz von characters (Thomas Höhne) ,– Werbeabgabe: Erlass zur Besteuerung der Prospektwerbung– Neu geboren